Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.48 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.36 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.32 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3303524 | 0.95 | ADORA1 (0.51) | ADORA1OPRM1ADORA3 | |
| SCHEMBL3311804 | 0.94 | ADORA1 (0.48) | ADORA1ADORA3 | |
| SCHEMBL1820411 | 0.89 | ADORA1 (0.51) | ADORA1ADORA3 | |
| SCHEMBL1815879 | 0.89 | ADORA1 (0.51) | ADORA1OPRM1ADORA3 | |
| SCHEMBL1815004 | 0.87 | ADORA1 (0.51) | ADORA1ADORA3 | |
| SCHEMBL3305073 | 0.86 | ADORA1 (0.49) | ADORA1ADORA3 | |
| SCHEMBL1814784 | 0.80 | OPRM1 (0.38) | OPRM1P2RX7 | |
| SCHEMBL1817959 | 0.76 | ADORA1 (0.44) | ADORA1ADORA3 | |
| SCHEMBL3305030 | 0.75 | ADORA1 (0.81) | ADORA1ADORA3 | |
| SCHEMBL1816105 | 0.74 | KDM4E (0.44) | OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2321296-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | Bayer Schering Pharma Aktiengesellschaft (DE) | 2011-05-18 | — | — | EP | disclosed |
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-04-22 | — | — | US | disclosed |
| WO-2010020363-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-02-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100099681-A1 | SUBSTITUTED 5-AMINOPYRAZOLES AND USE THEREOF | CYP3A5, ABAT, TPMT | ADORA1 724/4885OPRM1 3853/4885ADORA3 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.